Handok saw the highest growth of 0.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Handok’s patent filings and grants. Buy the databook here.
Handok has been focused on protecting inventions in South Korea(KR) with two publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings and grants with nearly 50% filings and 33% grants. The South Korea(KR), Australia(AU), Canada(CA), and European Patent Office(EPO) patent Office are among the top ten patent offices where Handok is filings its patents. Among the top granted patent authorities, Handok has 33% of its grants in South Korea(KR), 33% in Canada(CA) and 33% in European Patent Office(EPO).
Rani Therapeutics and Soleno Therapeutics could be the strongest competitors for Handok
In terms of grant share, Handok stands in sixth position among its competitors. Rani Therapeutics and Soleno Therapeutics secured the top positions according to recent patent publication data.
Patents related to rare diseases lead Handok's portfolio
Handok has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q2 2024.
Lung cancer related patents lead Handok portfolio followed by pancreatic cancer, and pain
Handok has highest number of patents in lung cancer followed by pancreatic cancer, pain, skin inflammation, and hypopituitarism. For lung cancer, nearly 8% of patents were filed and 8% of patents were granted in Q2 2024.
For comprehensive analysis of Handok's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.